News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
589,859 Results
Type
Article (43764)
Company Profile (92)
Press Release (545996)
Multimedia
Podcasts (80)
Webinars (15)
Section
Business (159195)
Career Advice (2493)
Deals (28885)
Drug Delivery (112)
Drug Development (76600)
Employer Resources (142)
FDA (14407)
Job Trends (12718)
News (284309)
Policy (28149)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2662)
Academic (1)
Accelerated approval (32)
Adcomms (29)
Allergies (141)
Alliances (40452)
ALS (175)
Alzheimer's disease (1705)
Antibody-drug conjugate (ADC) (307)
Approvals (14626)
Artificial intelligence (489)
Autoimmune disease (145)
Automation (36)
Bankruptcy (316)
Best Places to Work (10282)
BIOSECURE Act (17)
Biosimilars (173)
Biotechnology (68)
Bladder cancer (154)
Brain cancer (58)
Breast cancer (625)
Cancer (4695)
Cardiovascular disease (411)
Career advice (2114)
Career pathing (36)
CAR-T (275)
CDC (46)
Cell therapy (723)
Cervical cancer (30)
Clinical research (65758)
Collaboration (1527)
Company closure (4)
Compensation (647)
Complete response letters (63)
COVID-19 (2677)
CRISPR (92)
C-suite (876)
Cystic fibrosis (131)
Data (6077)
Decentralized trials (2)
Denatured (13)
Depression (146)
Diabetes (488)
Diagnostics (6153)
Digital health (38)
Diversity (8)
Diversity, equity & inclusion (39)
Drug discovery (232)
Drug pricing (175)
Drug shortages (26)
Duchenne muscular dystrophy (233)
Earnings (60897)
Editorial (57)
Employer branding (19)
Employer resources (134)
Events (82436)
Executive appointments (981)
FDA (17366)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (21)
Funding (1328)
Gene editing (194)
Generative AI (45)
Gene therapy (610)
GLP-1 (983)
Government (4527)
Grass and pollen (7)
Guidances (381)
Healthcare (16699)
HIV (57)
Huntington's disease (50)
IgA nephropathy (85)
Immunology and inflammation (274)
Immuno-oncology (58)
Indications (103)
Infectious disease (2954)
Inflammatory bowel disease (185)
Inflation Reduction Act (13)
Influenza (119)
Intellectual property (235)
Interviews (531)
IPO (13091)
IRA (49)
Job creations (2753)
Job search strategy (1710)
JPM (56)
Kidney cancer (18)
Labor market (60)
Layoffs (538)
Leadership (37)
Legal (5965)
Liver cancer (96)
Longevity (10)
Lung cancer (656)
Lymphoma (368)
Machine learning (36)
Management (51)
Manufacturing (689)
MASH (177)
Medical device (11405)
Medtech (11450)
Mergers & acquisitions (16756)
Metabolic disorders (1263)
Multiple sclerosis (161)
NASH (23)
Neurodegenerative disease (330)
Neuropsychiatric disorders (94)
Neuroscience (2958)
Neurotech (1)
NextGen: Class of 2026 (5792)
Non-profit (4194)
Now hiring (55)
Obesity (589)
Opinion (274)
Ovarian cancer (163)
Pain (201)
Pancreatic cancer (219)
Parkinson's disease (275)
Partnered (30)
Patents (471)
Patient recruitment (482)
Peanut (53)
People (53626)
Pharmaceutical (19)
Pharmacy benefit managers (19)
Phase 1 (20026)
Phase 2 (28917)
Phase 3 (22246)
Pipeline (5094)
Policy (278)
Postmarket research (2390)
Preclinical (8234)
Press Release (60)
Prostate cancer (231)
Psychedelics (55)
Radiopharmaceuticals (251)
Rare diseases (861)
Real estate (4473)
Recruiting (60)
Regulatory (21956)
Reports (30)
Research institute (2311)
Resumes & cover letters (365)
Rett syndrome (28)
RNA editing (16)
RSV (74)
Schizophrenia (153)
Series A (217)
Series B (170)
Service/supplier (4)
Sickle cell disease (101)
Special edition (17)
Spinal muscular atrophy (160)
Sponsored (38)
Startups (2968)
State (2)
Stomach cancer (19)
Supply chain (93)
Tariffs (77)
The Weekly (66)
Vaccines (996)
Venture capital (83)
Weight loss (394)
Women's health (75)
Worklife (19)
Date
Today (41)
Last 7 days (479)
Last 30 days (1790)
Last 365 days (26921)
2026 (3075)
2025 (27261)
2024 (31483)
2023 (35243)
2022 (45854)
2021 (49268)
2020 (47877)
2019 (41226)
2018 (31423)
2017 (28293)
2016 (26998)
2015 (31536)
2014 (23727)
2013 (19385)
2012 (20621)
2011 (21641)
2010 (19219)
Location
Africa (764)
Alabama (76)
Alaska (4)
Arizona (215)
Arkansas (13)
Asia (36696)
Australia (7362)
California (9479)
Canada (3011)
China (1061)
Colorado (399)
Connecticut (389)
Delaware (315)
Europe (81809)
Florida (1526)
Georgia (316)
Hawaii (2)
Idaho (54)
Illinois (768)
India (61)
Indiana (455)
Iowa (18)
Japan (403)
Kansas (117)
Kentucky (33)
Louisiana (25)
Maine (60)
Maryland (1251)
Massachusetts (6729)
Michigan (287)
Minnesota (514)
Mississippi (5)
Missouri (124)
Montana (25)
Nebraska (24)
Nevada (108)
New Hampshire (79)
New Jersey (2760)
New Mexico (26)
New York (2610)
North Carolina (1206)
North Dakota (7)
Northern California (4591)
Ohio (286)
Oklahoma (10)
Oregon (31)
Pennsylvania (1972)
Puerto Rico (24)
Rhode Island (41)
South America (1040)
South Carolina (61)
South Dakota (1)
Southern California (3767)
Tennessee (144)
Texas (1570)
United States (34428)
Utah (310)
Vermont (1)
Virginia (248)
Washington D.C. (66)
Washington State (818)
West Virginia (4)
Wisconsin (87)
Wyoming (2)
589,859 Results for "immutep formerly known as prima biomed".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immutep Quarterly Activities Report Q2 FY26
January 29, 2026
·
16 min read
Press Releases
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
February 8, 2026
·
4 min read
Press Releases
Immutep Quarterly Activities Report Q1 FY26
October 30, 2025
·
10 min read
Press Releases
Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
December 17, 2025
·
4 min read
Press Releases
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
October 21, 2025
·
5 min read
Press Releases
Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
December 23, 2025
·
5 min read
Press Releases
Immutep Announces Successful Completion of FDA Project Optimus Requirements
October 14, 2025
·
3 min read
Press Releases
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
December 3, 2025
·
4 min read
Press Releases
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
November 4, 2025
·
1 min read
Press Releases
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 28, 2025
·
4 min read
1 of 58,986
Next
